ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura

被引:0
作者
Minola Manea
AnnCharlotte Kristoffersson
Han-Mou Tsai
Wenhua Zhou
Ingemar Winqvist
Göran Oldaeus
Rolf Billström
Peter Björk
Lars Holmberg
Diana Karpman
机构
[1] Clinical Sciences Lund,Department of Pediatrics
[2] Lund University,Division of Hematology
[3] Montefiore Medical Center and Albert Einstein College of Medicine,Department of Hematology
[4] Lund University Hospital,Department of Pediatrics
[5] Länssjukhuset Ryhov,Department of Hematology
[6] Kärnsjukhuset,Department of Medicine
[7] Malmö University Hospital,undefined
来源
European Journal of Pediatrics | 2007年 / 166卷
关键词
ADAMTS13; von Willebrand factor; Thrombotic thrombocytopenic purpura; Immunoblotting; Plasma; von Willebrand factor cleaving protease;
D O I
暂无
中图分类号
学科分类号
摘要
The activity of ADAMTS13, the von Willebrand factor cleaving protease, is deficient in patients with thrombotic thrombocytopenic purpura (TTP). In the present study, the phenotype of ADAMTS13 in TTP and in normal plasma was demonstrated by immunoblotting. Normal plasma (n = 20) revealed a single band at 190 kD under reducing conditions using a polyclonal antibody, and a single band at 150 kD under non-reducing conditions using a monoclonal antibody. ADAMTS13 was not detected in the plasma from patients with congenital TTP (n = 5) by either antibody, whereas patients with acquired TTP (n = 2) presented the normal phenotype. Following immunoadsorption of immunoglobulins, the ADAMTS13 band was removed from the plasma of the patients with acquired TTP, but not from that of normal individuals. This indicates that ADAMTS13 is complexed with immunoglobulin in these patients. The lack of ADAMTS13 expression in the plasma from patients with hereditary TTP may indicate defective synthesis, impaired cellular secretion, or enhanced degradation in the circulation. This study differentiated between normal and TTP plasma, as well as between congenital and acquired TTP. This method may, therefore, be used as a complement in the diagnosis of TTP.
引用
收藏
页码:249 / 257
页数:8
相关论文
共 402 条
[1]  
Amar S(2002)Evaluation of ADAMTS-13 von Willebrand factor-cleaving metalloprotease activity using a rapid endothelial cell surface-based assay in two chronic relapsing TTP patients receiving plasma infusion Blood 100 684a-3977
[2]  
Rice L(2002)Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers Blood 99 3971-479
[3]  
Dong J-F(1985)Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen Thromb Res 38 469-1999
[4]  
Chow T(2003)Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency Kidney Int 63 1995-431
[5]  
Nolasco L(2006)A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders Kidney Int 70 423-713
[6]  
Bernardo A(2002)von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura Blood 100 710-435
[7]  
Baker KR(2002)Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13) Ann Hematol 81 430-32
[8]  
Moake JL(2002)Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome N Engl J Med 346 23-1209
[9]  
Arya M(2003)Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate Thromb Haemost 90 1204-4039
[10]  
Anvari B(2002)ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions Blood 100 4033-962